SynenTec to Acquire Roche’s Cell Imaging System

Roche (Basil, Switzerland) and SynenTec (Elmshorn, Germany) reported that Roche would transfer its Cellavista business to SynenTec, the company that was the original developer of the Cellavista system.

This agreement was a result of the Roche Applied Science decision to focus its business and assures future optimal support and development of the technology for its customers. The Cellavista imaging system for noninvasively measuring cell expansion employs brightfield and fluorescence detection with multiwell plates, chamber slides or RoboFlasks, for a broad range of cellular applications in cell line development, cellular research, and drug discovery.

“It is very important that we ensure uninterrupted support for our customers. We have found the ideal match in SynenTec,” said Dan Zabrowski, head of Roche Applied Science.

“This acquisition adds significant value for Cellavista customers by enabling them to directly discuss their requirements and needs with the developer of the system,” stated Matthias Pirsch, CEO of SynenTec.

Over the last several years, SynenTec collaborated with Roche in cell imaging, and was closely involved in the development, service, and support of Cellavista systems. With this business transfer, SynenTec will take on worldwide distribution of Cellavista systems, as well as providing application support and service. Roche will remain the primary contact partner for all support needs for Cellavista systems delivered by Roche or Innovatis over a transition phase until SynenTec assumes full responsibility on June 1, 2013.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the world’s largest biotech companies with differentiated medicines in oncology, virology, inflammation, metabolism, and central nervous system (CNS). Roche is also a developer of in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management.

Related Links:
Roche
SynenTec